Methods for treating glaucoma or ocular hypertension comprising delivery of prostaglandins to the vitreous humour
US11147855B2 · kind B2 · utility
0Cited by
0References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 18, 2019 |
| Grant date | Oct 19, 2021 |
| Priority date | — |
| Expiry date | Mar 28, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P27/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This disclosure relates to a drug delivery system comprising an intraocular pressure lowering agent, a neurotrophic agent, such as a CNTF compound, a C-type Natriuretic Peptide (CNP) compound, a Tie-2 agonist, a Natriuretic Peptide Receptor-B (NPR-B) compound, or an apoptosis signaling fragment inhibitor (FAS) or FAS-ligand (FASL) inhibitor, including any combination of these compounds and a sustained delivery component. Methods of treating a glaucoma or related conditions, medicaments, kits, uses and methods of manufacturing are also described.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.